Human Bcl9-2 Antibody

Catalog #: AF4967
5 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF4967
AF4967-SP

Detection of Human Bcl9‑2 by Western Blot.

1 Image

All Bcl9-2 Antibodies

Product Details

Citations (5)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Bcl9-2 Antibody Summary

Species Reactivity

Human

Specificity

Detects endogenous human Bcl9-2 in Western blots.

Source

Polyclonal Sheep IgG

Purification

Antigen Affinity-purified

Immunogen

E. coli-derived recombinant human Bcl9-2
Met38-Val206
Accession # Q86UU0

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Human Bcl9‑2 by Western Blot. Western blot shows lysates of A172 human glioblastoma cell line and MCF-7 human breast cancer cell line. PVDF membrane was probed with 1 µg/mL of Human Bcl9-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4967) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Bcl9-2 at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Bcl9-2

Bcl9-2 (B-cell lymphoma 9-like protein; also Bcl9L and B9L) is a 200-220 kDa transcriptional regulator that belongs to the Bcl9 family of proteins. It is expressed in multiple tissues, particularly breast, and serves to recruit Pygopus to the Wnt-pathway beta -catenin-TCF complex in the nucleus. Bcl9-2 and Bcl9 are considered evolutionary duplicates of Legless that perform the same task with different regulation. Human Bcl9-2 is 1499 amino acids (aa) in length. It contains two Pro-rich regions (aa 280-493 and 891-1378). There are four potential alternate start sites at Met879, Met1000, Met708 and Met472. The last two start sites are accompanied by a deletion of aa 1241-1286, and a 62 aa substitution for the C-terminal 167 aa, respectively. Over aa 38-206, human Bcl9-2 is 94% aa identical to mouse Bcl9-2. Bcl9-2 has been identified as a phosphoprotein in several human cancer cell lines and mouse liver.

Long Name

B Cell Lymphoma/Leukemia 9-like Protein

Entrez Gene IDs

283149 (Human); 80288 (Mouse); 300673 (Rat)

Alternate Names

B-cell CLL/lymphoma 9-like protein; B-cell CLL/lymphoma 9-like; B-cell lymphoma 9-like protein; Bcl92; Bcl9-2; BCL9-like protein; DLNB11; DLNB11BCL9-2; nuclear co-factor of beta-catenin signalling; Protein BCL9-2

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Wnt Intracellular Signaling

Citations for Human Bcl9-2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

Targeted Disruption of the BCL9/ beta -Catenin Complex Inhibits Oncogenic Wnt Signaling
Authors: Kohichi Takada, Di Zhu, Gregory H. Bird, Kumar Sukhdeo, Jian-Jun Zhao, Mala Mani et al.
Science Translational Medicine
Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites
Authors: NA Watson, TN Cartwright, C Lawless, M Cámara-Don, O Sen, K Sako, T Hirota, H Kimura, JMG Higgins
Nat Commun, 2020-04-03;11(1):1684.
Species: Human
Sample Types: Cell Culture Lysates
Applications: ELISA Capture
Pharmacological inhibition of ?-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells
Authors: M Feng, JQ Jin, L Xia, T Xiao, S Mei, X Wang, X Huang, J Chen, M Liu, C Chen, S Rafi, AX Zhu, YX Feng, D Zhu
Sci Adv, 2019-05-08;5(5):eaau5240.
Species: N/A
Sample Types: Peptides
Applications: Immunoprecipitation
Bcl9 and Pygo synergise downstream of Apc to effect intestinal neoplasia in FAP mouse models
Authors: J Mieszczane, LM van Tienen, AEK Ibrahim, DJ Winton, M Bienz
Nat Commun, 2019-02-13;10(1):724.
Species: Human
Sample Types: Whole Cells
Applications: ICC
Role of BCL9L in transforming growth factor-beta (TGF-beta )-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer
Authors: Giuseppina Sannino, Nicole Armbruster, Mona Bodenhöfer, Ursula Haerle, Diana Behrens, Malte Buchholz et al.
Oncotarget